These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

940 related items for PubMed ID: 27373139

  • 1. Novel antidiabetic drugs and cardiovascular risk: Primum non nocere.
    Bonadonna RC, Borghi C, Consoli A, Volpe M.
    Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):759-66. PubMed ID: 27373139
    [Abstract] [Full Text] [Related]

  • 2. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH.
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [Abstract] [Full Text] [Related]

  • 3. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM, Al Yami MS, Alshibani M, Fallatah SB, Al Khushaym NM, Alsheikh R, Alkhatib N.
    Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ.
    Circ Res; 2018 May 11; 122(10):1439-1459. PubMed ID: 29748368
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
    Secrest MH, Udell JA, Filion KB.
    Trends Cardiovasc Med; 2017 Apr 11; 27(3):194-202. PubMed ID: 28291655
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cardiovascular safety of therapies for type 2 diabetes.
    Gupta P, White WB.
    Expert Opin Drug Saf; 2017 Jan 11; 16(1):13-25. PubMed ID: 27652617
    [Abstract] [Full Text] [Related]

  • 10. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, Sambevski S, Bessette LG, Santiago Ortiz AJ, Kulldorff M, Schneeweiss S.
    Circulation; 2019 Jun 18; 139(25):2822-2830. PubMed ID: 30955357
    [Abstract] [Full Text] [Related]

  • 11. Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
    Shigiyama F, Kumashiro N, Fuchigami A, Hirose T.
    Cardiovasc Diabetol; 2018 Jun 12; 17(1):86. PubMed ID: 29895330
    [Abstract] [Full Text] [Related]

  • 12. [Treatment of patients with type 2 diabetes mellitus: cardiovascular safety of incretin-based therapy supported by the ELIXA and TECOS trials].
    Avogaro A.
    G Ital Cardiol (Rome); 2016 Apr 12; 17(4):248-52. PubMed ID: 27093207
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cardiovascular Effects of Incretin-Based Therapies.
    White WB, Baker WL.
    Annu Rev Med; 2016 Apr 12; 67():245-60. PubMed ID: 26768240
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ.
    Circulation; 2017 Aug 29; 136(9):849-870. PubMed ID: 28847797
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.